Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

EP: 1.Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

EP: 2.CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing

Now Viewing

EP: 3.Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

EP: 4.Protocol Development for Administration and AE Management of Bispecifics

EP: 5.Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management

EP: 6.Exploring the Management of Cytokine Release Syndrome (CRS)

EP: 7.Academic Perspectives for Evaluating, Identifying, and Managing CRS

EP: 8.Community Oncologist Perspective: Evaluating, Identifying, and Managing CRS

EP: 9.Clinical Recommendations for Neurological Toxicities

EP: 10.Community Oncologist Perspective: Clinical Recommendations for Neurological Toxicities

EP: 11.Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications

EP: 12.Community Oncologist Perspective: Initiation, Hospitalization, and Monitoring of Bispecifics

EP: 13.Patient Referrals of Bispecifics and Collaborative Efforts with Community Centers

EP: 14.Perceptions on the Future of Bispecific Therapies for NHL

EP: 15.Community Oncologist Perspective: Future of Bispecific Therapies for NHL

Video content above is prompted by the following:

1. This presentation is to do a deep dive into the operationalization of bispecific antibody (BsAb) therapy in community practices.

• Please summarize the toxicities observed with CD3×CD20 BsAbs.

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy